

Baekkeskov et al.
Serial No.: 08/857,486
Page 2

At p. 27, line 17, please delete "Immobilonr" and replace with --IMMOBILON® membrane--

At p. 29, line 4, please delete "Sepharose" and replace with --SEPHAROSE™--.

At p. 37, line 14 after "forms" please insert --(see Fig. 8)--.

IN THE CLAIMS

Please cancel claims 32, 33, 36 and 37 without prejudice. Please amend the claims as follows. Unamended pending claims are reproduced in small type for ease of reference.

B2 Sub A1
31. (Amended) A method for inhibiting the development of insulin dependent diabetes mellitus, said method comprising administering to a patient a [preselected] therapeutically effective dosage of glutamic acid decarboxylase (GAD) [or a fragment thereof].

B2
34. (Amended) A method as in claim 31, wherein the dosage of glutamic acid decarboxylase is [selected to induce tolerance in the patient to the 64kD autoantigen associated with insulin dependent diabetes] 1-500 mg of the glutamic acid decarboxylase or fragment per kg patient body weight.

B2
35. (Amended) A composition comprising glutamic acid decarboxylase [or a fragment thereof] in a pharmaceutically acceptable carrier for administration to a human patient.

Please add the following new claims

49. The method of claim 31, wherein the GAD is GAD65.

B4 Sub A1
50. The method of claim 31, wherein the GAD is recombinant GAD.